Novartis AG (NVS)
Automate Your Wheel Strategy on NVS
With Tiblio's Option Bot, you can configure your own wheel strategy including NVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVS
- Rev/Share 29.269
- Book/Share 23.2357
- PB 5.6672
- Debt/Equity 0.7224
- CurrentRatio 0.8812
- ROIC 0.1851
- MktCap 255238415476.0
- FreeCF/Share 8.8572
- PFCF 14.9621
- PE 17.4548
- Debt/Assets 0.2985
- DivYield 0.0306
- ROE 0.3412
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVS | BofA Securities | Neutral | Buy | -- | -- | Nov. 25, 2025 |
| Downgrade | NVS | Goldman | Neutral | Sell | -- | $118 | Sept. 12, 2025 |
| Upgrade | NVS | Morgan Stanley | Underweight | Equal Weight | -- | $123 | Aug. 8, 2025 |
| Downgrade | NVS | UBS | Buy | Neutral | -- | -- | Feb. 13, 2025 |
| Initiation | NVS | Morgan Stanley | -- | Underweight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVS | Deutsche Bank | Hold | Buy | -- | -- | Feb. 4, 2025 |
| Downgrade | NVS | HSBC Securities | Hold | Reduce | -- | -- | Dec. 4, 2024 |
| Downgrade | NVS | BofA Securities | Buy | Neutral | $135 | $130 | Sept. 11, 2024 |
| Downgrade | NVS | Goldman | Buy | Neutral | -- | -- | Sept. 5, 2024 |
| Downgrade | NVS | Jefferies | Buy | Hold | -- | -- | Sept. 3, 2024 |
News
Here's Why Novartis (NVS) is a Strong Momentum Stock
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
Read More
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
Read More
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
Published: November 20, 2025 by: Benzinga
Sentiment: Positive
Novartis AG (NYSE: NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.
Read More
Novartis to build manufacturing hub in North Carolina, creating 700 jobs
Published: November 19, 2025 by: Reuters
Sentiment: Positive
Novartis will expand its operations in North Carolina and build a manufacturing hub there as part of a planned $23 billion of U.S. infrastructure investment over the next five years, the Swiss pharmaceuticals company said on Wednesday.
Read More
Novartis announces plans to build flagship manufacturing hub in North Carolina
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Basel, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with end-to-end manufacturing capabilities. The strategic investment is a major step to ensure all key Novartis medicines for US patients are manufactured in the US and delivered to patients across the country at scale. This announcement is part of Novartis' $23 billion investment in US-based infrastructure over the next five years, designed to increase manufacturing capacity and enable 100% of the company's key medicines to be produced end-to-end in the US. As …
Read More
Novartis announces plans to build flagship manufacturing hub in North Carolina
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
East Hanover, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with end-to-end manufacturing capabilities. The strategic investment is a major step to ensure all key Novartis medicines for US patients are manufactured in the US and delivered to patients across the country at scale.
Read More
Here's Why Novartis (NVS) is a Strong Value Stock
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
Read More
Novartis AG (NVS) Q3 2025 Earnings Call Transcript
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NYSE:NVS ) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Matthew Weston - UBS Investment Bank, Research Division Peter Verdult - BNP Paribas Exane, Research Division Steve Scala - TD Cowen, Research Division Xue Chen - Barclays Bank PLC, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Read More
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Read More
Compared to Estimates, Novartis (NVS) Q3 Earnings: A Look at Key Metrics
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Novartis (NVS) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Novartis AG (NVS) M&A Call Transcript
Published: October 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NYSE:NVS ) M&A Call October 27, 2025 8:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Robert Baloh Norman Putzki - Global Program Head of Neuroscience Conference Call Participants Sachin Jain - BofA Securities, Research Division Harry Sephton Seamus Fernandez - Guggenheim Securities, LLC, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Read More
Novartis Agrees to Acquire Avidity Biosciences for $12 Billion
Published: October 26, 2025 by: WSJ
Sentiment: Positive
The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
Read More
Novartis to acquire Avidity Biosciences for about $12B
Published: October 26, 2025 by: New York Post
Sentiment: Neutral
Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for autoimmune diseases.
Read More
Novartis Deal Values Avidity Biosciences At $12 Billion
Published: October 26, 2025 by: Barrons
Sentiment: Positive
The acquisition would raise the 2024-2029 expected sales compound annual growth rate for Novartis to 6% from 5%, it said.
Read More
Novartis to acquire Avidity Biosciences for $12 billion
Published: October 26, 2025 by: Reuters
Sentiment: Positive
Swiss drugmaker Novartis on Sunday said it agreed to acquire Avidity Biosciences for $12 billion.
Read More
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
Published: October 26, 2025 by: PRNewsWire
Sentiment: Neutral
Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a new company ("SpinCo") Closing expected in 1H2026 subject to completion of the separation of SpinCo from Avidity and other customary closing conditions SAN DIEGO , Oct. 26, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it has entered into a definitive merger agreement …
Read More
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
Published: October 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases Advances the Novartis xRNA strategy by adding a scientifically robust, muscle-directed, Antibody Oligonucleotide Conjugates (AOCs™) platform and first-in-disease pipeline Expected to unlock multi-billion-dollar opportunities with planned product launches before 2030 Raises expected 2024-2029 sales CAGR for Novartis from +5% to +6%, and bolsters mid-single digit long-term growth As part of the agreement, Avidity will separate its early-stage precision cardiology programs into a new company (“SpinCo”) prior to closing Consideration totals USD 12bn in cash; closing expected in …
Read More
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
Published: October 26, 2025 by: CNBC
Sentiment: Positive
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
Read More
Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Read More
Novartis: Assessing The Impact Of Entresto Generics
Published: October 16, 2025 by: Seeking Alpha
Sentiment: Positive
Entresto generics have finally arrived in the U.S. in July, and approximately 9% of Novartis' revenue will be impacted. The growth of other key products and of Entresto in ex-U.S. territories should be enough for mid-single-digit revenue growth rates through the Entresto erosion period. The late-stage pipeline is thin, with few major catalysts between now and 2027, and management continues to guide only bolt-on acquisitions.
Read More
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
Read More
Here's Why Novartis (NVS) is a Strong Value Stock
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Read More
3 Reasons Growth Investors Will Love Novartis (NVS)
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
About Novartis AG (NVS)
- IPO Date 1996-11-07
- Website https://www.novartis.com
- Industry Drug Manufacturers - General
- CEO Vasant Narasimhan
- Employees 75883